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SHORT COMMUNICATION
Expression of CA125 in pancreatic carcinoma and chronic pancreatitis
F. Macdonald, R. Downing & W.H. Allum
Department of Surgery, University of Birmingham, Birmingham, UK.
Several markers have been evaluated for the diagnosis of
pancreatic cancer including carcinoembryonic antigen (CEA),
CA19-9, CA50 and pancreatic oncofoetal antigen (POA).
CEA can be demonstrated immunohistochemically in pan-
creatic adenocarcinomas and in pancreatic tissues from
patients with chronic pancreatitis (Allum et al., 1986). CA19-
9 is expressed by a variety of gastrointestinal tract tumours
including pancreatic carcinomas (Atkinson et al., 1982) but
is also found in association with acute and chronic pancrea-
titis and in the ductal cells of the normal pancreas (Haglund
et al., 1986b). Serum levels of CA50 were found to be
elevated in 71% of patients with pancreatic cancer but were
also elevated in 29% of patients with benign pancreatic
diseases (Haglund et al., 1987). CA125 was originally identi-
fied as a marker of non-mucinous ovarian tumours but
elevated serum levels have been found in patients with
gastrointestinal malignancy (Klug et al., 1984). Haglund
(1986), found raised serum levels of CA125 in 45% of
patients with pancreatic cancer and in 24% of patients with
benign pancreatic disease but was unable to identify the
source of CA125. In our study, the expression of CA125 in
tissue sections of pancreatic cancer and chronic pancreatitis
has been assessed by an immunohistochemical method.
Excised pancreatic tissue and pancreatic biopsies were
obtained from nine patients with chronic pancreatitis and 29
patients with pancreatic cancer - 7 poorly differentiated, 11
moderately differentiated and 11 well differentiated adeno-
carcinomas of exocrine origin as assessed independently by
the pathologist at the time of initial surgery. All tissues were
formalin fixed, embedded in paraffin and 6,um sections cut
from each block. We have previously shown that such
processing does not destroy the CA125 antigen (Macdonald
et al., 1988). CA125 was detected by modification of an
indirect immunoperoxidase assay, as described by the manu-
facturers (CIS UK). Briefly, endogenous peroxidase activity
was blocked with hydrogen peroxide in methanol and tissue
sections incubated with 1 mgml-1 pronase (Protease Type
XIV, Sigma) 'in phosphate buffered saline' (PBS) for 20min
at room temperature to increase the intensity of CA125
staining (Shishi et al., 1986). Sections were washed twice in
PBS for 5min and treated with first antibody - OC125 -
followed by biotinylated anti-mouse and an avidin-biotin
complex reagent. 3-amino-9-carbazole was used as substrate
and sections mounted in 'Aquamount'. Slides were assessed
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for intensity of staining, scored from negative to + + +, and
for the percentage of tumour cells which expressed CA125
by two independent observers. One section in which OC125
was replaced with PBS served as a negative control and a
section of ovarian tumour known to express CA125 was
used as a positive control.
Results are shown in Table I. In 3 out of 9 cases of
chronic pancreatitis, staining was noted on the apical surface
of ductal cells. Only one section from a poorly differentiated
tumour stained but <5% of cells were positive. In contrast,
55% of moderately differentiated tumours and 91% of well-
differentiated tumours expressed CA125 and in 27% of these
tumours, over 50% of cells in each section were positive
(Table I). Staining was seen in the cytoplasm and on the
luminal surfaces of both well and moderately differentiated
tumours (Figure 1) and was occasionally seen in the cells
lining the larger ducts.
These results suggest that CA125 is produced by pan-
creatic tumour cells themselves and may explain the high
levels of the antigen seen in the sera of patients with
pancreatic cancer. Several other sources of CA125 are likely
- 50% of patients with poorly differentiated pancreatic
tumours have high serum levels of CA125 (Haglund, 1986)
whereas our study suggests that such tumours express the
antigen at a very low level.
The role of CA125 in the diagnosis of pancreatic cancer is
Figure 1 Section of a well differentiated tumour showing strong
expression of CA125. ( x 400).
Table I Expression of CA125 in benign and malignant pancreatic lesions
Number Staining intensity % Cells positive
Histology tested -ve + ++ +++ -ve <25 25-50 >50
Chronic pancreatitis 9 6 3 6 3
All adenocarcinoma 29 12 7 9 1 12 11 1 5
Poorly differentiated 7 6 1 6 1
Moderately differentiated 11 5 1 5 5 4 2
Well differentiated 11 1 5 4 1 1 6 1 3
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uncertain. CA19-9 and CEA are expressed in a higher
percentage of pancreatic tumour tissues than CA125
(Haglund et al., 1986; Allum et al., 1986) but CA125 is
detected less often in chronic pancreatitis (30%) compared to
the other two markers (96% and 40% respectively). Estima-
tion of serum levels of CA125 has been suggested as a
method of distinguishing between benign and malignant
pancreatic disease.
Finally, OC125 could be included in a panel of antibodies
for antibody guided therapy and localisation of pancreatic
tumours. In ovarian cancer, CA125 was shown to be
expressed by a different population of cells to those express-
ing CAl9-9 (Macdonald et al., 1988) and this may be true of
other tumours. Confirmation of this remains to be deter-
mined for pancreatic tumours.
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